Viventia Bio is developing next generation oncology therapeutics utilizing our proprietary Targeted Protein Therapeutic technology (TPT). Our novel TPTs have been designed to overcome the efficacy and safety challenges of existing antibody-drug conjugates.

from http://www.viventia.com/about/company-overview

Patents show all

38Applications31Issued

Clinical Trials show all

2Phase 21Phase 11Phase 2/Phase 31Phase 3

Overview

Total FundingEmployeesLast Funding DateStatus
11-50Acquired